Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan - 1 Jan 2012

Okazaki Keinosuke, Watanabe Toru, Saito Isao, Murayama Jun-Ichiro

Abstract excerpt

Our aim was to clarify the side effects of irinotecan which occurred in patients admitted to Showa University Hospital to investigate whether the UGT1A1 genetic polymorphism status was reflected in the discontinuation or dose reduction of irinotecan. We retrospectively investigated UGT1A1 genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Neoplasms

Share to Neutropenia

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 22293705
DOI: 10.1248/yakushi.132.231

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22293705-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Examination of factors affecting adverse reactions and dosage reduction in UGT1A1 genotyped patients: a retrospective survey of irinotecan].PMID 22293705Read ↗

[UGT1A1 Genotyping for Proper Use of Irinotecan].Semantic proximity Read ↗

[Relationship between UGT1A and irinotecan-related toxicity].Semantic proximity Read ↗

[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].Semantic proximity Read ↗

[Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].Semantic proximity Read ↗

Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patientsSemantic proximity Read ↗

[Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)].Semantic proximity Read ↗

UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.Semantic proximity Read ↗

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.Semantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Pharmacogenetics and irinotecan therapy.Semantic proximity Read ↗

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.Semantic proximity Read ↗

UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.